Therapy Areas: Diabetes
Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker
7 September 2021 - - Canada-based peripheral CB1 blockade company Inversago Pharma Inc has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound, the company said.

The move follows the receipt of a No Objection Letter from Health Canada on July 29, 2021.

As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome, non-alcoholic steatohepatitis, type 1 diabetes, diabetic nephropathy and chronic kidney diseases, among others.

INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions.

It is specifically designed to preferentially interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers.

The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.

Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.

The company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as PWS, NASH, T1D and diabetic nephropathy.
Login
Username:

Password: